Edition:
India

Ludwig Burger

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

02 Jul 2020

FRANKFURT A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

01 Jul 2020

FRANKFURT, July 1 A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations

30 Jun 2020

Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.

Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech

29 Jun 2020

FRANKFURT Singapore's state investor Temasek and other investors are injecting $250 million into German biotech company BioNTech , which is developing an experimental vaccine against the coronavirus with pharmaceutical giant Pfizer .

Bayer to pay up to $10.9 billion to settle bulk of Roundup weedkiller cancer lawsuits

25 Jun 2020

FRANKFURT/NEW YORK Bayer AG, after more than a year of talks, agreed to pay as much as $10.9 billion to settle close to 100,000 U.S. lawsuits claiming that its widely-used weedkiller Roundup caused cancer, resolving litigation that has pummeled the company's share price. | Video

AstraZeneca eyes three-drug inhaler opportunity after trial results

24 Jun 2020

AstraZeneca is eyeing the further growth of its respiratory treatments business as a three-drug inhaler was shown to prevent flare-ups and death in cases of smoker's lung.

RPT-GSK in quest to be best, not first, in race for COVID-19 vaccine

22 Jun 2020

FRANKFURT, June 19 There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline.

GSK in quest to be best, not first, in race for COVID-19 vaccine

20 Jun 2020

FRANKFURT There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline .

World News